The CSF1/CSF1R axis is physiologically critical but can drive pathological changes in a variety of biological processes impacting multiple organs such as lung, liver and kidney. Leveraging its mechanistic insight into the CSF1/CSF1R biology, AmMax is building and expanding the anti-inflammatory, anti-fibrotic and anti-neovascular technology platform targeting CSF1R that has promising therapeutic potential across a wide range of critical disease states.
AmMax’s robust pipeline based on the CSF1R platform captures either best-in-class or first-in-class opportunities that have clinical or preclinical validation/support, are well-differentiated and positioned to bring significant clinical benefits to patients.
With a seasoned management team, a versatile technology platform and a robust pipeline, AmMax is poised to grow into a leading biotech company.
Launched in March 2020 out of a partnership between LifeMax and Amgen, AmMax Bio, Inc. (“AmMax”) is a privately held, clinical stage biotech company focused on unlocking the therapeutic potential of the CSF1R platform (“colony stimulating factor 1 receptor”) to address diseases with significant unmet medical needs and sizable market potential. We have two clinical stage programs ready to enter Phase 2 studies.
AmMax has a very experienced management team, led by Dr. Larry Hsu, co-founder and former CEO of Impax Laboratories, Inc., which he successfully built into a fully integrated multi-billion dollar publicly traded pharmaceutical company. With broad experience across therapeutic areas and therapeutic modalities, the AmMax team is strong in execution and has collectively brought multiple BLAs, NDAs and MAAs to approval and commercialization.